Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Naidoo, K., Wai, P.T., Maguire, S.L., Daley, F., Haider, S., Kriplani, D., Campbell, J., Mirza, H., Grigoriadis, A., Tutt, A., et al. (2018). Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. Mol cancer ther, Vol.17 (1), pp. 306-315.  show abstract

Touat, M., Sourisseau, T., Dorvault, N., Chabanon, R.M., Garrido, M., Morel, D., Krastev, D.B., Bigot, L., Adam, J., Frankum, J.R., et al. (2018). DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. J clin invest, Vol.128 (4), pp. 1671-1687.  show abstract

Natrajan, R., Tutt, A.N. & Lord, C.J. (2018). Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. Cancer discov, Vol.8 (3), pp. 272-275.  show abstract

Bajrami, I., Marlow, R., van de Ven, M., Brough, R., Pemberton, H.N., Frankum, J., Song, F., Rafiq, R., Konde, A., Krastev, D.B., et al. (2018). E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Cancer discov, Vol.8 (4), pp. 498-515.  show abstract

Khalique, S., Naidoo, K., Attygalle, A.D., Kriplani, D., Daley, F., Lowe, A., Campbell, J., Jones, T., Hubank, M., Fenwick, K., et al. (2018). Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. J pathol clin res, Vol.4 (3), pp. 154-166.  show abstract

Noordermeer, S.M., Adam, S., Setiaputra, D., Barazas, M., Pettitt, S.J., Ling, A.K., Olivieri, M., Álvarez-Quilón, A., Moatti, N., Zimmermann, M., et al. (2018). The shieldin complex mediates 53BP1-dependent DNA repair. Nature, Vol.560 (7716), pp. 117-121.  show abstract

Ryan, C.J., Bajrami, I. & Lord, C.J. (2018). Synthetic Lethality and Cancer - Penetrance as the Major Barrier. Trends cancer, Vol.4 (10), pp. 671-683.  show abstract

Pettitt, S.J., Krastev, D.B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M.I., Menon, M., Brough, R., Campbell, J., et al. (2018). Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat commun, Vol.9 (1), p. 1849.  show abstract

Holme, H., Gulati, A., Brough, R., Fleuren, E.D., Bajrami, I., Campbell, J., Chong, I.Y., Costa-Cabral, S., Elliott, R., Fenton, T., et al. (2018). Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Sci rep, Vol.8 (1), p. 10614.  show abstract

Barazas, M., Annunziato, S., Pettitt, S.J., de Krijger, I., Ghezraoui, H., Roobol, S.J., Lutz, C., Frankum, J., Song, F.F., Brough, R., et al. (2018). The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. Cell rep, Vol.23 (7), pp. 2107-2118.  show abstract

Brough, R., Gulati, A., Haider, S., Kumar, R., Campbell, J., Knudsen, E., Pettitt, S.J., Ryan, C.J. & Lord, C.J. (2018). Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene, .  show abstract

Krastev, D.B., Pettitt, S.J., Campbell, J., Song, F., Tanos, B.E., Stoynov, S.S., Ashworth, A. & Lord, C.J. (2018). Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. Nat commun, Vol.9 (1), p. 2016.  show abstract

Ashworth, A. & Lord, C.J. (2018). Synthetic lethal therapies for cancer: what's next after PARP inhibitors?. Nat rev clin oncol, .  show abstract

Witkiewicz, A.K., Chung, S., Brough, R., Vail, P., Franco, J., Lord, C.J. & Knudsen, E.S. (2018). Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. Cell rep, Vol.22 (5), pp. 1185-1199.  show abstract

Campbell, J., Ryan, C.J. & Lord, C.J. (2018). Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels. Methods mol biol, Vol.1711, pp. 83-99.  show abstract

Jansen, S., Geuer, S., Pfundt, R., Brough, R., Ghongane, P., Herkert, J.C., Marco, E.J., Willemsen, M.H., Kleefstra, T., Hannibal, M., et al. (2017). De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome. Am j hum genet, Vol.100 (4), pp. 650-658.  show abstract

Brandsma, I., Fleuren, E.D., Williamson, C.T. & Lord, C.J. (2017). Directing the use of DDR kinase inhibitors in cancer treatment. Expert opin investig drugs, Vol.26 (12), pp. 1341-1355.  show abstract

Ryan, C.J., Kennedy, S., Bajrami, I., Matallanas, D. & Lord, C.J. (2017). A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events. Cell syst, Vol.5 (4), pp. 399-409.e5.  show abstract

Bridgett, S., Campbell, J., Lord, C.J. & Ryan, C.J. (2017). CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. Cell syst, Vol.5 (1), pp. 82-86.e3.  show abstract

Nikkilä, J., Kumar, R., Campbell, J., Brandsma, I., Pemberton, H.N., Wallberg, F., Nagy, K., Scheer, I., Vertessy, B.G., Serebrenik, A.A., et al. (2017). Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Br j cancer, Vol.117 (1), pp. 113-123.  show abstract

Lord, C.J. & Ashworth, A. (2016). BRCAness revisited. Nat rev cancer, Vol.16 (2), pp. 110-120.  show abstract

Beck, D., Zobel, J., Barber, R., Evans, S., Lezina, L., Allchin, R.L., Blades, M., Elliott, R., Lord, C.J., Ashworth, A., et al. (2016). Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma. J biol chem, Vol.291 (32), pp. 16686-16698.  show abstract

Herrera-Abreu, M.T., Palafox, M., Asghar, U., Rivas, M.A., Cutts, R.J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016). Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016). Cancer research, Vol.76 (19), pp. 5907-5907.

Dréan, A., Lord, C.J. & Ashworth, A. (2016). PARP inhibitor combination therapy. Crit rev oncol hematol, Vol.108, pp. 73-85.  show abstract

Campbell, J., Ryan, C.J., Brough, R., Bajrami, I., Pemberton, H.N., Chong, I.Y., Costa-Cabral, S., Frankum, J., Gulati, A., Holme, H., et al. (2016). Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell rep, Vol.14 (10), pp. 2490-2501.  show abstract

Costa-Cabral, S., Brough, R., Konde, A., Aarts, M., Campbell, J., Marinari, E., Riffell, J., Bardelli, A., Torrance, C., Lord, C.J., et al. (2016). Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. Plos one, Vol.11 (4), p. e0154007.

Costa-Cabral, S., Brough, R., Konde, A., Aarts, M., Campbell, J., Marinari, E., Riffell, J., Bardelli, A., Torrance, C., Lord, C.J., et al. (2016). CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. Plos one, Vol.11 (2), p. e0149099.  show abstract

Vollan, H.K., Rueda, O.M., Chin, S.-., Curtis, C., Turashvili, G., Shah, S., Lingjærde, O.C., Yuan, Y., Ng, C.K., Dunning, M.J., et al. (2015). A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Mol oncol, Vol.9 (1), pp. 115-127.  show abstract

Aarts, M., Bajrami, I., Herrera-Abreu, M.T., Elliott, R., Brough, R., Ashworth, A., Lord, C.J. & Turner, N.C. (2015). Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Mol cancer ther, Vol.14 (4), pp. 865-876.  show abstract

Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., Gillett, C., Pinder, S., Vanoli, F., Jasin, M., et al. (2015). Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. Cancer discov, Vol.5 (5), pp. 488-505.  show abstract

Francis, J.C., Melchor, L., Campbell, J., Kendrick, H., Wei, W., Armisen-Garrido, J., Assiotis, I., Chen, L., Kozarewa, I., Fenwick, K., et al. (2015). Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours. J pathol, Vol.236 (2), pp. 186-200.  show abstract

Kwon, Y.-., Petrie, K., Leibovitch, B.A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., et al. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Mol cancer ther, Vol.14 (8), pp. 1824-1836.  show abstract

Frankum, J., Moudry, P., Brough, R., Hodny, Z., Ashworth, A., Bartek, J. & Lord, C.J. (2015). Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. Oncotarget, Vol.6 (13), pp. 10746-10758.  show abstract

Conti, A., Majorini, M.T., Elliott, R., Ashworth, A., Lord, C.J., Cancelliere, C., Bardelli, A., Seneci, P., Walczak, H., Delia, D., et al. (2015). Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. Oncotarget, Vol.6 (13), pp. 10994-11008.  show abstract

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015). DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N engl j med, Vol.373 (18), pp. 1697-1708.  show abstract

Elliott, R.J., Jarvis, A., Rajasekaran, M.B., Menon, M., Bowers, L., Boffey, R., Bayford, M., Firth-Clark, S., Key, R., Aqil, R., et al. (2015). Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors. Medchemcomm, Vol.6 (9), pp. 1687-1692.

Lord, C.J., Tutt, A.N. & Ashworth, A. (2015). Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu rev med, Vol.66, pp. 455-470.  show abstract

Bajrami, I., Frankum, J.R., Konde, A., Miller, R.E., Rehman, F.L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014). Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer res, Vol.74 (1), pp. 287-297.  show abstract

Murugaesu, N., Iravani, M., van Weverwijk, A., Ivetic, A., Johnson, D.A., Antonopoulos, A., Fearns, A., Jamal-Hanjani, M., Sims, D., Fenwick, K., et al. (2014). An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer discov, Vol.4 (3), pp. 304-317.  show abstract

Natrajan, R., Wilkerson, P.M., Marchiò, C., Piscuoglio, S., Ng, C.K., Wai, P., Lambros, M.B., Samartzis, E.P., Dedes, K.J., Frankum, J., et al. (2014). Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J pathol, Vol.232 (5), pp. 553-565.  show abstract

McDade, S.S., Patel, D., Moran, M., Campbell, J., Fenwick, K., Kozarewa, I., Orr, N.J., Lord, C.J., Ashworth, A.A. & McCance, D.J., et al. (2014). Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress. Nucleic acids res, Vol.42 (10), pp. 6270-6285.  show abstract

Ryan, C.J., Lord, C.J. & Ashworth, A. (2014). DAISY: picking synthetic lethals from cancer genomes. Cancer cell, Vol.26 (3), pp. 306-308.  show abstract

Rajan, N., Elliott, R.J., Smith, A., Sinclair, N., Swift, S., Lord, C.J. & Ashworth, A. (2014). The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling. Oncotarget, Vol.5 (23), pp. 12126-12140.

Gao, S., Bajrami, I., Verrill, C., Kigozi, A., Ouaret, D., Aleksic, T., Asher, R., Han, C., Allen, P., Bailey, D., et al. (2014). Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. Cancer res, Vol.74 (20), pp. 5866-5877.  show abstract

Wetterskog, D., Shiu, K.-., Chong, I., Meijer, T., Mackay, A., Lambros, M., Cunningham, D., Reis-Filho, J.S., Lord, C.J. & Ashworth, A., et al. (2014). Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers. Oncogene, Vol.33 (8), pp. 966-976.  show abstract

Shiu, K.-., Wetterskog, D., Mackay, A., Natrajan, R., Lambros, M., Sims, D., Bajrami, I., Brough, R., Frankum, J., Sharpe, R., et al. (2014). Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. Oncogene, Vol.33 (5), pp. 619-631.  show abstract

Bhandari, D., Zhang, J., Menon, S., Lord, C., Chen, S., Helm, J.R., Thorsen, K., Corbett, K.D., Hay, J.C. & Ferro-Novick, S., et al. (2013). Sit4p/PP6 regulates ER-to-Golgi traffic by controlling the dephosphorylation of COPII coat subunits. Molecular biology of the cell, Vol.24 (17), pp. 2727-2738.

Ang, J.E., Gourley, C., Powell, C.B., High, H., Shapira-Frommer, R., Castonguay, V., De Greve, J., Atkinson, T., Yap, T.A., Sandhu, S., et al. (2013). Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin cancer res, Vol.19 (19), pp. 5485-5493.  show abstract

Neijenhuis, S., Bajrami, I., Miller, R., Lord, C.J. & Ashworth, A. (2013). Identification of miRNA modulators to PARP inhibitor response. Dna repair (amst), Vol.12 (6), pp. 394-402.  show abstract

Barber, L.J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D.N., Reis Filho, J.S., Moreno, V., et al. (2013). Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J pathol, Vol.229 (3), pp. 422-429.  show abstract

Pettitt, S.J., Rehman, F.L., Bajrami, I., Pemberton, H., Brough, R., Kozarewa, I., Lord, C.J. & Ashworth, A. (2013). A transposon-based genetic screen in haploid mouse embryonic stem cells identifies Parp1 as a major mediator of olaparib toxicity. Molecular cancer therapeutics, Vol.12 (5).

Fontebasso, Y., Lord, C.J. & Ashworth, A. (2013). Induced aggravation of oxidative DNA damage as a targeted synthetic lethal approach in mismatch repair-deficient tumors. Molecular cancer therapeutics, Vol.12 (5).

Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D.A., Carvalho, D., Taylor, K.R., Vinci, M., et al. (2013). Histone H3 3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer discov, Vol.3 (5), pp. 512-519.  show abstract

Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D.A., Carvalho, D., Taylor, K.R., Vinci, M., et al. (2013). Histone H3 3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN. Cancer discovery, Vol.3 (5), pp. 512-519.

Sandhu, S.K., Omlin, A., Hylands, L., Miranda, S., Barber, L.J., Riisnaes, R., Reid, A.H., Attard, G., Chen, L., Kozarewa, I., et al. (2013). Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann oncol, Vol.24 (5), pp. 1416-1418.

Hewish, M., Martin, S.A., Elliott, R., Cunningham, D., Lord, C.J. & Ashworth, A. (2013). Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. Br j cancer, Vol.108 (4), pp. 983-992.  show abstract

Mereniuk, T.R., El Gendy, M.A., Mendes-Pereira, A.M., Lord, C.J., Ghosh, S., Foley, E., Ashworth, A. & Weinfeld, M. (2013). Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase. Mol cancer ther, Vol.12 (10), pp. 2135-2144.  show abstract

Chong, I.Y., Cunningham, D., Barber, L.J., Campbell, J., Chen, L., Kozarewa, I., Fenwick, K., Assiotis, I., Guettler, S., Garcia-Murillas, I., et al. (2013). The genomic landscape of oesophagogastric junctional adenocarcinoma. Journal of pathology, Vol.231 (3), pp. 301-310.

Lord, C.J. & Ashworth, A. (2013). Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat med, Vol.19 (11), pp. 1381-1388.  show abstract

Natrajan, R.C., Leonidou, A., Brough, R., Frankum, J., Wai, P.T., Ng, C.K., Reis-Filho, J.S., Lord, C.J. & Ashworth, A. (2013). Integrated genomic analyses of members of protein kinase C family identifies subtype specific alterations as novel therapeutic targets. Cancer research, Vol.73.

Shen, Y., Rehman, F.L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C.J., Post, L.E. & Ashworth, A., et al. (2013). BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin cancer res, Vol.19 (18), pp. 5003-5015.  show abstract

Ruark, E., Snape, K., Humburg, P., Loveday, C., Bajrami, I., Brough, R., Rodrigues, D.N., Renwick, A., Seal, S., Ramsay, E., et al. (2013). Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature, Vol.493 (7432), pp. 406-410.  show abstract

Postel-Vinay, S., Bajrami, I., Friboulet, L., Elliott, R., Fontebasso, Y., Dorvault, N., Olaussen, K.A., André, F., Soria, J.-., Lord, C.J., et al. (2013). A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene, Vol.32 (47), pp. 5377-5387.  show abstract

Pettitt, S.J., Rehman, F.L., Bajrami, I., Brough, R., Wallberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013). A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. Plos one, Vol.8 (4), p. e61520.  show abstract

Hewish, M., Stamp, G., Puckey, L., Shanley, S., Costello, C., Webb, J., Hulkki Wilson, S., Gonzalez de Castro, D., Barbachano, Y., Saffery, C., et al. (2012). Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice. J clin oncol, Vol.30 (4_suppl), p. 603.  show abstract

Walker, B.A., Wardell, C.P., Melchor, L., Hulkki, S., Potter, N.E., Johnson, D.C., Fenwick, K., Kozarewa, I., Gonzalez, D., Lord, C.J., et al. (2012). Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood, Vol.120 (5), pp. 1077-1086.  show abstract

Turajlic, S., Furney, S.J., Lambros, M.B., Mitsopoulos, C., Kozarewa, I., Geyer, F.C., Mackay, A., Hakas, J., Zvelebil, M., Lord, C.J., et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome res, Vol.22 (2), pp. 196-207.  show abstract

Postel-Vinay, S., Vanhecke, E., Olaussen, K.A., Lord, C.J., Ashworth, A. & Soria, J.-. (2012). The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nature reviews clinical oncology, Vol.9 (3), pp. 144-155.

Turnbull, C., Loveday, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J.R., Warren-Perry, M., Snape, K., Eccles, D., Evans, D.G., et al. (2012). Newly discovered high-intermediate penetrance ovarian cancer susceptibility genes: clinical testing of RAD51D and RAD51C may have significant utility. International journal of gynecological cancer, Vol.22, pp. S42-S42.

Natrajan, R., Mackay, A., Lambros, M.B., Weigelt, B., Wilkerson, P.M., Manie, E., Grigoriadis, A., A'Hern, R., van der Groep, P., Kozarewa, I., et al. (2012). A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. J pathol, Vol.227 (1), pp. 29-41.  show abstract

Stratford, A.L., Reipas, K., Hu, K., Fotovati, A., Brough, R., Frankum, J., Takhar, M., Watson, P., Ashworth, A., Lord, C.J., et al. (2012). Targeting p90 Ribosomal S6 Kinase Eliminates Tumor-Initiating Cells by Inactivating Y-Box Binding Protein-1 in Triple-Negative Breast Cancers. Stem cells, Vol.30 (7), pp. 1338-1348.

Furney, S.J., Turajlic, S., Fenwick, K., Lambros, M.B., MacKay, A., Ricken, G., Mitsopoulos, C., Kozarewa, I., Hakas, J., Zvelebil, M., et al. (2012). Genomic characterisation of acral melanoma cell lines. Pigment cell melanoma res, Vol.25 (4), pp. 488-492.  show abstract

Brough, R., Bajrami, I., Vatcheva, R., Natrajan, R., Reis-Filho, J.S., Lord, C.J. & Ashworth, A. (2012). APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. Embo journal, Vol.31 (5), pp. 1160-1176.

Iorns, E., Ward, T.M., Dean, S., Jegg, A., Thomas, D., Murugaesu, N., Sims, D., Mitsopoulos, C., Fenwick, K., Kozarewa, I., et al. (2012). Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. Breast cancer res treat, Vol.135 (1), pp. 79-91.  show abstract

McDade, S.S., Henry, A.E., Pivato, G.P., Kozarewa, I., Mitsopoulos, C., Fenwick, K., Assiotis, I., Hakas, J., Zvelebil, M., Orr, N., et al. (2012). Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation. Nucleic acids res, Vol.40 (15), pp. 7190-7206.  show abstract

Daemen, A., Wolf, D.M., Korkola, J.E., Griffith, O.L., Frankum, J.R., Brough, R., Jakkula, L.R., Wang, N.J., Natrajan, R., Reis-Filho, J.S., et al. (2012). Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast cancer research and treatment, Vol.135 (2), pp. 505-517.

Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C.J. & Ashworth, A. (2012). Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. Embo mol med, Vol.4 (10), pp. 1087-1096.  show abstract

Rehman, F.L., Lord, C.J. & Ashworth, A. (2012). The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy. Cancer discovery, Vol.2 (11), pp. 982-984.

Riffell, J.L., Lord, C.J. & Ashworth, A. (2012). Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat rev drug discov, Vol.11 (12), pp. 923-936.  show abstract

Murugaesu, N., Iravani, M., Johnson, D., Antonopoulos, A., Sims, D., Fenwick, K., Mitsopoulos, C., Gao, Q., Orr, N., Zvelebil, M., et al. (2012). An in vivo functional screen to identify metastasis suppressor genes. Cancer research, Vol.72.

Mackay, A.G., Natrajan, R., Maher, C., Lambros, M., Weigelt, B., Nava-Rodrigues, D., Wilkerson, P., CampionFlora, A., Kozarewa, I., Fenwick, K., et al. (2012). Integrative genomic and transcriptomic analysis of metaplastic carcinomas of the breast. Cancer research, Vol.72.

Ng, C.K., Gauthier, A., Mackay, A., Lambros, M.B., Rodrigues, D.N., Arnoud, L., Lacroix-Triki, M., Penault-Llorca, F., Baranzelli, M.C., Sastre-Garau, X., et al. (2012). Genomic characterisation of invasive breast cancers with heterogeneous HER2 gene amplification. Cancer research, Vol.72.

Lord, C.J. & Ashworth, A. (2012). The DNA damage response and cancer therapy. Nature, Vol.481 (7381), pp. 287-294.  show abstract

Mendes-Pereira, A.M., Sims, D., Dexter, T., Fenwick, K., Assiotis, I., Kozarewa, I., Mitsopoulos, C., Hakas, J., Zvelebil, M., Lord, C.J., et al. (2012). Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc natl acad sci u s a, Vol.109 (8), pp. 2730-2735.  show abstract

Mendes-Pereira, A.M., Lord, C.J. & Ashworth, A. (2012). NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells. Plos one, Vol.7 (10).

Kozarewa, I., Rosa-Rosa, J.M., Wardell, C.P., Walker, B.A., Fenwick, K., Assiotis, I., Mitsopoulos, C., Zvelebil, M., Morgan, G.J., Ashworth, A., et al. (2012). A modified method for whole exome resequencing from minimal amounts of starting DNA. Plos one, Vol.7 (3), p. e32617.  show abstract

Martin, S.A., Hewish, M., Sims, D., Lord, C.J. & Ashworth, A. (2011). Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer res, Vol.71 (5), pp. 1836-1848.  show abstract

Ashworth, A., Lord, C.J. & Reis-Filho, J.S. (2011). Genetic interactions in cancer progression and treatment. Cell, Vol.145 (1), pp. 30-38.  show abstract

Cerone, M.A., Burgess, D.J., Naceur-Lombardelli, C., Lord, C.J. & Ashworth, A. (2011). High-throughput RNAi screening reveals novel regulators of telomerase. Cancer res, Vol.71 (9), pp. 3328-3340.  show abstract

Brough, R., Frankum, J.R., Costa-Cabral, S., Lord, C.J. & Ashworth, A. (2011). Searching for synthetic lethality in cancer. Curr opin genet dev, Vol.21 (1), pp. 34-41.  show abstract

Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J.R., Bowden, G., Kalmyrzaev, B., Warren-Perry, M., Snape, K., et al. (2011). Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat genet, Vol.43 (9), pp. 879-882.  show abstract

Rajan, N., Burn, J., Langtry, J., Sieber-Blum, M., Lord, C.J. & Ashworth, A. (2011). Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression. J pathol, Vol.224 (3), pp. 309-321.  show abstract

Brough, R., Frankum, J.R., Sims, D., Mackay, A., Mendes-Pereira, A.M., Bajrami, I., Costa-Cabral, S., Rafiq, R., Ahmad, A.S., Cerone, M.A., et al. (2011). Functional viability profiles of breast cancer. Cancer discov, Vol.1 (3), pp. 260-273.  show abstract

Rovillain, E., Mansfield, L., Lord, C.J., Ashworth, A. & Jat, P.S. (2011). An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence. Bmc genomics, Vol.12, p. 355.  show abstract

Wilkerson, P.M., Dedes, K.J., Wetterskog, D., Mackay, A., Lambros, M.B., Mansour, M., Frankum, J., Lord, C.J., Natrajan, R., Ashworth, A., et al. (2011). Functional characterization of EMSY gene amplification in human cancers. J pathol, Vol.225 (1), pp. 29-42.  show abstract

Vaughan, S., Coward, J.I., Bast, R.C., Berchuck, A., Berek, J.S., Brenton, J.D., Coukos, G., Crum, C.C., Drapkin, R., Etemadmoghadam, D., et al. (2011). Rethinking ovarian cancer: recommendations for improving outcomes. Nat rev cancer, Vol.11 (10), pp. 719-725.  show abstract

Rajan, N., Elliott, R., Clewes, O., Mackay, A., Reis-Filho, J.S., Burn, J., Langtry, J., Sieber-Blum, M., Lord, C.J. & Ashworth, A., et al. (2011). Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene, Vol.30 (41), pp. 4243-4260.  show abstract

Wilkerson, P., Dedes, K.J., Wetterskog, D., Natrajan, R., Lambros, M.B., Mackay, A., Lord, C.J., Ashworth, A. & Reis-Filho, J.S. (2011). EMSY amplification and overexpression is not associated with defective homologous recombination and does not predict sensitivity to cisplatin or PARP inhibitors. Cancer research, Vol.71.

Hewish, M., Lord, C.J., Martin, S.A., Cunningham, D. & Ashworth, A. (2011). High-throughput drug screens identify novel synthetic lethal interactions with MLH1-deficient cancers. Cancer research, Vol.71.

Wetterskog, D., Shiu, K.-., Chong, I., Meijer, T., Natrajan, R., Lord, C.J., Ashworth, A. & Reis-Filho, J.S. (2011). Identification of novel genes and pathways involved in resistance to HER2-targeting agents in breast cancer. Cancer research, Vol.71.

Natrajan, R., Maher, C.A., Lambros, M.B., Pawar, V., Wetterskog, D., Marchio, C., Barbashina, V., Geyer, F.C., Fenwick, K., Kozarewa, I., et al. (2011). Massively parallel RNA sequencing analysis of micropapillary carcinomas of the breast. Cancer research, Vol.71.

Daemen, A., Wolf, D.M., Korkola, J.E., Griffith, O.L., Frankum, J.R., Jakkula, L.R., Wang, N.J., Natrajan, R., Reis-Filho, J.S., Lord, C.J., et al. (2011). Identification of Biomarkers in Breast Cancer for Prediction of Response to PARP Inhibitor Olaparib. Cancer research, Vol.71.

Ha, K.C., Lalonde, E., Li, L., Cavallone, L., Natrajan, R., Lambros, M.B., Mitsopoulos, C., Hakas, J., Kozarewa, I., Fenwick, K., et al. (2011). Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. Bmc med genomics, Vol.4, p. 75.  show abstract

Tanas, M.R., Sboner, A., Oliveira, A.M., Erickson-Johnson, M.R., Hespelt, J., Hanwright, P.J., Flanagan, J., Luo, Y., Fenwick, K., Natrajan, R., et al. (2011). Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci transl med, Vol.3 (98), p. 98ra82.  show abstract

Sims, D., Mendes-Pereira, A.M., Frankum, J., Burgess, D., Cerone, M.-., Lombardelli, C., Mitsopoulos, C., Hakas, J., Murugaesu, N., Isacke, C.M., et al. (2011). High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. Genome biology, Vol.12 (10).

Barber, L.J., Rosa Rosa, J.M., Kozarewa, I., Fenwick, K., Assiotis, I., Mitsopoulos, C., Sims, D., Hakas, J., Zvelebil, M., Lord, C.J., et al. (2011). Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. Plos one, Vol.6 (7), p. e21639.  show abstract

Martin, S.A., Lord, C.J. & Ashworth, A. (2010). Therapeutic Targeting of the DNA Mismatch Repair Pathway. Clin cancer res, Vol.16 (21), pp. 5107-5113.  show abstract

Martin, S.A., Hewish, M., Lord, C.J. & Ashworth, A. (2010). Genomic instability and the selection of treatments for cancer. J pathol, Vol.220 (2), pp. 281-289.  show abstract

Sourisseau, T., Maniotis, D., McCarthy, A., Tang, C., Lord, C.J., Ashworth, A. & Linardopoulos, S. (2010). Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. Embo mol med, Vol.2 (4), pp. 130-142.  show abstract

Hewish, M., Lord, C.J., Martin, S.A., Cunningham, D. & Ashworth, A. (2010). Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat rev clin oncol, Vol.7 (4), pp. 197-208.  show abstract

Natrajan, R., Weigelt, B., Mackay, A., Geyer, F.C., Grigoriadis, A., Tan, D.S., Jones, C., Lord, C.J., Vatcheva, R., Rodriguez-Pinilla, S.M., et al. (2010). An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast cancer res treat, Vol.121 (3), pp. 575-589.  show abstract

Lambros, M.B., Natrajan, R., Geyer, F.C., Lopez-Garcia, M.A., Dedes, K.J., Savage, K., Lacroix-Triki, M., Jones, R.L., Lord, C.J., Linardopoulos, S., et al. (2010). PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod pathol, Vol.23 (10), pp. 1334-1345.  show abstract

de Plater, L., Lauge, A., Guyader, C., Poupon, M.F., Assayag, F., de Cremoux, P., Vincent-Salomon, A., Stoppa-Lyonnet, D., Sigal-Zafrani, B., Fontaine, J.J., et al. (2010). Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Brit j cancer, Vol.103 (8), pp. 1192-1200.  show abstract

Rehman, F.L., Lord, C.J. & Ashworth, A. (2010). Synthetic lethal approaches to breast cancer therapy. Nat rev clin oncol, Vol.7 (12), pp. 718-724.  show abstract

Lord, C.J. & Ashworth, A. (2010). Biology-driven cancer drug development: back to the future. Bmc biol, Vol.8,  show abstract

Dedes, K.J., Wetterskog, D., Mendes-Pereira, A.M., Natrajan, R., Lambros, M.B., Geyer, F.C., Vatcheva, R., Savage, K., Mackay, A., Lord, C.J., et al. (2010). PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci transl med, Vol.2 (53), p. 53ra75.  show abstract

Graeser, M., McCarthy, A., Lord, C.J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I.E., Reis-Filho, J.S., et al. (2010). A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin cancer res, Vol.16 (24), pp. 6159-6168.  show abstract

Martin, S.A., McCabe, N., Mullarkey, M., Cummins, R., Burgess, D.J., Nakabeppu, Y., Oka, S., Kay, E., Lord, C.J. & Ashworth, A., et al. (2010). DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer cell, Vol.17 (3), pp. 235-248.  show abstract

Dedes, K.J., Wetterskog, D., Mendes-Pereira, A.M., Vatcheva, R., Natrajan, R., Lambros, M.B., Lord, C.J., Ashworth, A. & Reis-Filho, J.S. (2010). Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas. Journal of clinical oncology, Vol.28 (15).

Hewish, M., Saffery, C., Barbachano, Y., Wotherspoon, A., Brown, G., Martin, S.A., Lord, C.J., Chau, I., Ashworth, A. & Cunningham, D., et al. (2010). MESH: Phase II trial of methotrexate as a synthetic lethal therapy for metastatic MSH2-deficient colorectal and other tumors. Journal of clinical oncology, Vol.28 (15).

Tan, D.S., Lambros, M.B., Rayter, S., Natrajan, R., Vatcheva, R., Gao, Q., Marchio, C., Geyer, F.C., Savage, K., Parry, S., et al. (2009). PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas. Clin cancer res, Vol.15 (7), pp. 2269-2280.  show abstract

Iorns, E., Lord, C.J. & Ashworth, A. (2009). Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem j, Vol.417, pp. 361-370.  show abstract

Lord, C.J., Martin, S.A. & Ashworth, A. (2009). RNA interference screening demystified. J clin pathol, Vol.62 (3), pp. 195-200.  show abstract

McCabe, N., Cerone, M.A., Ohishi, T., Seimiya, H., Lord, C.J. & Ashworth, A. (2009). Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene, Vol.28 (11), pp. 1465-1470.  show abstract

Houlihan, S.J., Simpson, S.H., Cave, A.J., Flook, N.W., Hurlburt, M.E., Lord, C.J., Smith, L.L. & Sternberg, H.H. (2009). Hypertension treatment and control rates: chart review in an academic family medicine clinic. Can fam physician, Vol.55 (7), pp. 735-741.  show abstract

Martin, S.A., McCarthy, A., Barber, L.J., Burgess, D.J., Parry, S., Lord, C.J. & Ashworth, A. (2009). Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. Embo mol med, Vol.1 (6-7), pp. 323-337.  show abstract

Mendes-Pereira, A.M., Martin, S.A., Brough, R., McCarthy, A., Taylor, J.R., Kim, J.S., Waldman, T., Lord, C.J. & Ashworth, A. (2009). Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. Embo mol med, Vol.1 (6-7), pp. 315-322.  show abstract

Oliver, A.W., Swift, S., Lord, C.J., Ashworth, A. & Pearl, L.H. (2009). Structural basis for recruitment of BRCA2 by PALB2. Embo rep, Vol.10 (9), pp. 990-996.  show abstract

Iorns, E., Lord, C.J., Grigoriadis, A., McDonald, S., Fenwick, K., MacKay, A., Mein, C.A., Natrajan, R., Savage, K., Tamber, N., et al. (2009). Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets. Plos one, Vol.4 (4),  show abstract

Iorns, E., Martens-de Kemp, S.R., Lord, C.J. & Ashworth, A. (2009). CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. Carcinogenesis, Vol.30 (10), pp. 1696-1701.  show abstract

McCarthy, A., Lord, C.J., Savage, K., Grigoriadis, A., Smith, D.P., Weigelt, B., Reis-Filho, J.S. & Ashworth, A. (2009). Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation. J pathol, Vol.219 (3), pp. 306-316.  show abstract

Mackay, A., Tamber, N., Fenwick, K., Iravani, M., Grigoriadis, A., Dexter, T., Lord, C.J., Reis-Filho, J.S. & Ashworth, A. (2009). A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast cancer res treat, Vol.118 (3), pp. 481-498.  show abstract

Natrajan, R., Lambros, M.B., Rodríguez-Pinilla, S.M., Moreno-Bueno, G., Tan, D.S., Marchió, C., Vatcheva, R., Rayter, S., Mahler-Araujo, B., Fulford, L.G., et al. (2009). Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin cancer res, Vol.15 (8), pp. 2711-2722.  show abstract

Natrajan, R., Lambros, M.B., Rodriguez-Pinilla, S.M., Moreno-Bueno, G., Tan, D.S., Marchio, C., Vatcheva, R., Rayter, S., Mahler-Araujo, B., Fulford, L.G., et al. (2009). Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers. Clin cancer res, Vol.15 (8), pp. 2711-2722.  show abstract

Lord, C.J. & Ashworth, A. (2009). Bringing DNA Repair in Tumors into Focus. Clin cancer res, Vol.15 (10), pp. 3241-3243.  show abstract

Lord, C.J., Iorns, E. & Ashworth, A. (2008). Dissecting resistance to endocrine therapy in breast cancer. Cell cycle, Vol.7 (13), pp. 1895-1898.  show abstract

Lord, C.J., McDonald, S., Swift, S., Turner, N.C. & Ashworth, A. (2008). A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. Dna repair (amst), Vol.7 (12), pp. 2010-2019.  show abstract

Brough, R., Wei, D., Leulier, S., Lord, C.J., Rong, Y.S. & Ashworth, A. (2008). Functional analysis of Drosophila melanogaster BRCA2 in DNA repair. Dna repair (amst), Vol.7 (1), pp. 10-19.  show abstract

Martin, S.A., Lord, C.J. & Ashworth, A. (2008). DNA repair deficiency as a therapeutic target in cancer. Curr opin genet dev, Vol.18 (1), pp. 80-86.  show abstract

Iorns, E., Turner, N.C., Elliott, R., Syed, N., Garrone, O., Gasco, M., Tutt, A.N., Crook, T., Lord, C.J. & Ashworth, A., et al. (2008). Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer cell, Vol.13 (2), pp. 91-104.  show abstract

Turner, N.C., Lord, C.J., Iorns, E., Brough, R., Swift, S., Elliott, R., Rayter, S., Tutt, A.N. & Ashworth, A. (2008). A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. Embo j, Vol.27 (9), pp. 1368-1377.  show abstract

Lord, C.J. & Ashworth, A. (2008). Targeted therapy for cancer using PARP inhibitors. Curr opin pharmacol, Vol.8 (4), pp. 363-369.  show abstract

Marchiò, C., Natrajan, R., Shiu, K.K., Lambros, M.B., Rodriguez-Pinilla, S.M., Tan, D.S., Lord, C.J., Hungermann, D., Fenwick, K., Tamber, N., et al. (2008). The genomic profile of HER2-amplified breast cancers: the influence of ER status. J pathol, Vol.216 (4), pp. 399-407.  show abstract

Rayter, S., Elliott, R., Travers, J., Rowlands, M.G., Richardson, T.B., Boxall, K., Jones, K., Linardopoulos, S., Workman, P., Aherne, W., et al. (2008). A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene, Vol.27 (8), pp. 1036-1044.  show abstract

Edwards, S.L., Brough, R., Lord, C.J., Natrajan, R., Vatcheva, R., Levine, D.A., Boyd, J., Reis-Filho, J.S. & Ashworth, A. (2008). Resistance to therapy caused by intragenic deletion in BRCA2. Nature, Vol.451 (7182), pp. 1111-1115.  show abstract

Komander, D., Lord, C.J., Scheel, H., Swift, S., Hofmann, K., Ashworth, A. & Barford, D. (2008). The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol cell, Vol.29 (4), pp. 451-464.  show abstract

Lord, C.J. & Ashworth, A. (2007). RAD51, BRCA2 and DNA repair: a partial resolution. Nat struct mol biol, Vol.14 (6), pp. 461-462.  show abstract

Iorns, E., Lord, C.J., Turner, N. & Ashworth, A. (2007). Utilizing RNA interference to enhance cancer drug discovery. Nat rev drug discov, Vol.6 (7), pp. 556-568.  show abstract

Gudmundsdottir, K., Lord, C.J. & Ashworth, A. (2007). The proteasome is involved in determining differential utilization of double-strand break repair pathways. Oncogene, Vol.26 (54), pp. 7601-7606.  show abstract

Smalley, M.J., Iravani, M., Leao, M., Grigoriadis, A., Kendrick, H., Dexter, T., Fenwick, K., Regan, J.L., Britt, K., McDonald, S., et al. (2007). Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. Breast cancer res, Vol.9 (6), p. R85.  show abstract

Lord, C.J., Garrett, M.D. & Ashworth, A. (2006). Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin cancer res, Vol.12 (15), pp. 4463-4468.  show abstract

Friedmann, B.J., Caplin, M., Savic, B., Shah, T., Lord, C.J., Ashworth, A., Hartley, J.A. & Hochhauser, D. (2006). Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol cancer ther, Vol.5 (2), pp. 209-218.  show abstract

Arias-Lopez, C., Lazaro-Trueba, I., Kerr, P., Lord, C.J., Dexter, T., Iravani, M., Ashworth, A. & Silva, A. (2006). P53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. Embo rep, Vol.7 (2), pp. 219-224.  show abstract

McCabe, N., Turner, N.C., Lord, C.J., Kluzek, K., Bialkowska, A., Swift, S., Giavara, S., O'Connor, M.J., Tutt, A.N., Zdzienicka, M.Z., et al. (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer res, Vol.66 (16), pp. 8109-8115.  show abstract

McCabe, N., Lord, C.J., Tutt, A.N., Martin, N.M., Smith, G.C. & Ashworth, A. (2005). BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer biol ther, Vol.4 (9), pp. 934-936.  show abstract

McCabe, N., Lord, C.J., Tutt, A.N., Martin, N.M., Smith, G.C. & Ashworth, A. (2005). BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-Ribose) polymerase. Cancer biol ther, Vol.4 (9), pp. 934-936.  show abstract

Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, Vol.434 (7035), pp. 917-921.  show abstract

Gudmundsdottir, K., Lord, C.J., Witt, E., Tutt, A.N. & Ashworth, A. (2004). DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. Embo rep, Vol.5 (10), pp. 989-993.  show abstract

Brook, F.A., Evans, E.P., Lord, C.J., Lyons, P.A., Rainbow, D.B., Howlett, S.K., Wicker, L.S., Todd, J.A. & Gardner, R.L. (2003). The derivation of highly germline-competent embryonic stem cells containing NOD-derived genome. Diabetes, Vol.52 (1), pp. 205-208.  show abstract

Penha-Gonçalves, C., Moule, C., Smink, L.J., Howson, J., Gregory, S., Rogers, J., Lyons, P.A., Suttie, J.J., Lord, C.J., Peterson, L.B., et al. (2003). Identification of a structurally distinct CD101 molecule encoded in the 950-kb Idd10 region of NOD mice. Diabetes, Vol.52 (6), pp. 1551-1556.  show abstract

Warren, M., Lord, C.J., Masabanda, J., Griffin, D. & Ashworth, A. (2003). Phenotypic effects of heterozygosity for a BRCA2 mutation. Hum mol genet, Vol.12 (20), pp. 2645-2656.  show abstract

Scott, J.M. & Lord, C.J. (2003). SGS Database: use of relational databases to enhance data management for multi-site experiments. Aust j exp agr, Vol.43 (7-8), pp. 729-743.  show abstract

Lord, C.J., Howlett, S., Lyons, P.A., Peterson, L.B., Wicker, L.S. & Todd, J.A. (2001). The murine type 1 diabetes loci, Idd1, Idd3, Idd5, Idd9, and Idd17/10/18, do not control thymic CD4-CD8-/TCRalphabeta+ deficiency in the nonobese diabetic mouse. Mamm genome, Vol.12 (2), pp. 175-176.

Cordell, H.J., Todd, J.A., Hill, N.J., Lord, C.J., Lyons, P.A., Peterson, L.B., Wicker, L.S. & Clayton, D.G. (2001). Statistical modeling of interlocus interactions in a complex disease: rejection of the multiplicative model of epistasis in type 1 diabetes. Genetics, Vol.158 (1), pp. 357-367.  show abstract

Lyons, P.A., Armitage, N., Lord, C.J., Phillips, M.S., Todd, J.A., Peterson, L.B. & Wicker, L.S. (2001). Mapping by genetic interaction - High-resolution congenic mapping of the type 1 diabetes loci Idd10 and Idd18 in the NOD mouse. Diabetes, Vol.50 (11), pp. 2633-2637.  show abstract

Lyons, P.A., Armitage, N., Argentina, F., Denny, P., Hill, N.J., Lord, C.J., Wilusz, M.B., Peterson, L.B., Wicker, L.S. & Todd, J.A., et al. (2000). Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping. Genome res, Vol.10 (4), pp. 446-453.  show abstract

Podolin, P.L., Wilusz, M.B., Cubbon, R.M., Pajvani, U., Lord, C.J., Todd, J.A., Peterson, L.B., Wicker, L.S. & Lyons, P.A. (2000). Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene?. Cytokine, Vol.12 (5), pp. 477-482.  show abstract

Lyons, P.A., Hancock, W.W., Denny, P., Lord, C.J., Hill, N.J., Armitage, N., Siegmund, T., Todd, J.A., Phillips, M.S., Hess, J.F., et al. (2000). The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity, Vol.13 (1), pp. 107-115.  show abstract

Podolin, P.L., Denny, P., Armitage, N., Lord, C.J., Hill, N.J., Levy, E.R., Peterson, L.B., Todd, J.A., Wicker, L.S. & Lyons, P.A., et al. (1998). Localization of two insulin-dependent diabetes (Idd) genes to the Idd10 region on mouse chromosome 3. Mamm genome, Vol.9 (4), pp. 283-286.  show abstract

Denny, P., Lord, C.J., Hill, N.J., Goy, J.V., Levy, E.R., Podolin, P.L., Peterson, L.B., Wicker, L.S., Todd, J.A. & Lyons, P.A., et al. (1997). Mapping of the IDDM locus Idd3 to a 0 35-cM interval containing the interleukin-2 gene. Diabetes, Vol.46 (4), pp. 695-700.  show abstract

Barnardo, M.C., Bunce, M., Lord, C.J. & Welsh, K.I. (1997). HLA-B*5603: sequence of a novel hybrid allele comprising B*56 and B*4601 segments. Tissue antigens, Vol.49 (5), pp. 496-498.

Podolin, P.L., Denny, P., Lord, C.J., Hill, N.J., Todd, J.A., Peterson, L.B., Wicker, L.S. & Lyons, P.A. (1997). Congenic mapping of the insulin-dependent diabetes (Idd) gene, Idd10, localizes two genes mediating the Idd10 effect and eliminates the candidate Fcgr1. J immunol, Vol.159 (4), pp. 1835-1843.  show abstract

Stecher, H.A., Krantz, D.E., Lord, C.J., Luther, G.W. & Bock, K.W. (1996). Profiles of strontium and barium in Mercenaria mercenaria and Spisula solidissima shells. Geochim cosmochim ac, Vol.60 (18), pp. 3445-3456.  show abstract

Lord, C.J., Bohlander, S.K., Hopes, E.A., Montague, C.T., Hill, N.J., Prins, J.B., Renjilian, R.J., Peterson, L.B., Wicker, L.S. & Todd, J.A., et al. (1995). Mapping the diabetes polygene Idd3 on mouse chromosome 3 by use of novel congenic strains. Mamm genome, Vol.6 (9), pp. 563-570.  show abstract

LORD, C.J. (1994). DETERMINATION OF LEAD AND LEAD-ISOTOPE RATIOS IN GASOLINE BY INDUCTIVELY-COUPLED PLASMA-MASS SPECTROMETRY. J anal atom spectrom, Vol.9 (5), pp. 599-603.  show abstract

LORD, C.J. (1994). VETERINARY NURSING EXAMINATIONS. Vet rec, Vol.135 (12), pp. 287-287.

LORD, C.J. (1993). VETERINARY NURSING EXAMINATIONS. Vet rec, Vol.133 (14), pp. 350-350.

LORD, C.J. (1991). DETERMINATION OF TRACE-METALS IN CRUDE-OIL BY INDUCTIVELY COUPLED PLASMA MASS-SPECTROMETRY WITH MICROEMULSION SAMPLE INTRODUCTION. Anal chem, Vol.63 (15), pp. 1594-1599.  show abstract

Pettitt, S. & Lord, C. PARP inhibitors and breast cancer – highlights and hang-ups. Expert review on precision medicine and drug development, .

Jones, S.E., Fleuren, E.D., Frankum, J., Konde, A., Williamson, C.T., Krastev, D.B., Pemberton, H.N., Campbell, J., Gulati, A., Elliott, R., et al. ATR Is a Therapeutic Target in Synovial Sarcoma. Cancer res, Vol.77 (24), pp. 7014-7026.  show abstract

Herrera-Abreu, M.T., Palafox, M., Asghar, U., Rivas, M.A., Cutts, R.J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer res, Vol.76 (8), pp. 2301-2313.  show abstract

Dréan, A., Williamson, C.T., Brough, R., Brandsma, I., Menon, M., Konde, A., Garcia-Murillas, I., Pemberton, H.N., Frankum, J., Rafiq, R., et al. Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Mol cancer ther, Vol.16 (9), pp. 2022-2034.  show abstract

Fleuren, E.D., Vlenterie, M., van der Graaf, W.T., Hillebrandt-Roeffen, M.H., Blackburn, J., Ma, X., Chan, H., Magias, M.C., van Erp, A., van Houdt, L., et al. Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes. Cancer res, Vol.77 (16), pp. 4279-4292.  show abstract

Rivera, B., Di Iorio, M., Frankum, J., Nadaf, J., Fahiminiya, S., Arcand, S.L., Burk, D.L., Grapton, D., Tomiak, E., Hastings, V., et al. Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. Cancer res, Vol.77 (16), pp. 4517-4529.  show abstract

Quigley, D., Alumkal, J.J., Wyatt, A.W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., et al. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer discov, Vol.7 (9), pp. 999-1005.  show abstract

Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D.R., Sandhu, S., et al. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer discov, Vol.7 (9), pp. 1006-1017.  show abstract

Lord, C.J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science, Vol.355 (6330), pp. 1152-1158.  show abstract

Pettitt, S.J., Krastev, D.B., Pemberton, H.N., Fontebasso, Y., Frankum, J., Rehman, F.L., Brough, R., Song, F., Bajrami, I., Rafiq, R., et al. Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells. Sci data, Vol.4, p. 170020.  show abstract

Williamson, C.T., Miller, R., Pemberton, H.N., Jones, S.E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat commun, Vol.7, p. 13837.  show abstract

Dhillon, K.K., Bajrami, I., Taniguchi, T. & Lord, C.J. Synthetic lethality: the road to novel therapies for breast cancer. Endocr relat cancer, Vol.23 (10), pp. T39-T55.  show abstract

Miller, R.E., Brough, R., Bajrami, I., Williamson, C.T., McDade, S., Campbell, J., Kigozi, A., Rafiq, R., Pemberton, H., Natrajan, R., et al. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. Mol cancer ther, Vol.15 (7), pp. 1472-1484.  show abstract

Maguire, S.L., Peck, B., Wai, P.T., Campbell, J., Barker, H., Gulati, A., Daley, F., Vyse, S., Huang, P., Lord, C.J., et al. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. J pathol, Vol.240 (3), pp. 315-328.  show abstract

Rajan, N., Andersson, M.K., Sinclair, N., Fehr, A., Hodgson, K., Lord, C.J., Kazakov, D.V., Vanecek, T., Ashworth, A. & Stenman, G., et al. Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells. J pathol, Vol.239 (2), pp. 197-205.  show abstract

Orr, N.J., Lemnrau, A., Cooke, R., Fletcher, O., Tomczyk, K., Jones, M., Johnson, N., Lord, C.J., Mitsopoulos, M., Zvelebil, M., et al. Genome-wide association study identifies a novel variant in RAD51B associated with male breast cancer risk. Nature genetics, .  show abstract


Conferences

Hewish, M., Fontebasso, Y., Martin, S.A., Elliott, R., Perks, K.L., Konde, A., Bajrami, I., Van Weverwijk, A., Cunningham, D., Lord, C.J., et al. (2014). Cancer cells deficient in DNA mismatch repair (MMR) are selectively sensitive to inhibition of the DNA dependent protein kinase (DNA-PK), CANCER RESEARCH, Vol.74 (19).

Fontebasso, Y., Hewish, M., Lord, C.J. & Ashworth, A. (2014). Exacerbation of oxidative DNA damage as a synthetic lethal approach in mismatch repair deficient tumors, CANCER RESEARCH, Vol.74 (19).

Barber, R., Zobel, J., Beck, D., Evans, S., Elliott, R., Lord, C.J., Ashworth, A., Porter, A.G. & Wagner, S.D. (2014). JAK2 Is a Direct BCL6 Target Gene: Implications for Therapy in Diffuse Large B-Cell Lymphoma, BLOOD, Vol.124 (21).

Miller, R.E., Bajrami, I., Brough, R., Konde, A., Campbell, J., Rafiq, R., Ashworth, A. & Lord, C.J. (2014). Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC), EUROPEAN JOURNAL OF CANCER, Vol.50, pp.103-104.

Pettitt, S.J., Krastev, D., Pemberton, H., Fontebasso, Y., Bajrami, I., Kozarewa, I., Frankum, J., Rafiq, R., Campbell, J., Brough, R., et al. (2014). Genome-wide drug sensitivity screens in haploid mouse embryonic stem cells, EUROPEAN JOURNAL OF CANCER, Vol.50, p.33.

Bajrami, I., Pettitt, S.J., Brough, R., Pemberton, H., Kastrev, D., Fontebasso, Y., Frankum, J., Campbell, J., Ashworth, A. & Lord, C.J., et al. (2014). An integrated approach for identifying E-cadherin synthetic lethality networks, EUROPEAN JOURNAL OF CANCER, Vol.50, p.50.

Chong, I.Y., Cunningham, D., Elliott, R., Konde, A., Campbell, J., Menon, M., Bowers, L., Daley, F., Lord, C.J. & Ashworth, A., et al. (2014). Candidate drug therapies for molecularly defined subgroups of esophageal cancer identified from high-throughput drug screening., JOURNAL OF CLINICAL ONCOLOGY, Vol.32 (15).

Chong, I.Y., Hooper, S.D., Cunningham, D., Elliott, R., Chen, L., Campbell, J., Bajrami, I., Kozarewa, I., Wetterskog, D., Wilkerson, P.M., et al. (2013). Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma, JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (4).

Natrajan, R., Wilkerson, P.M., Marchio, C., Lambros, M.B., Ng, C.K., Topfer, C., Kozarewa, I., Hakas, J., Mitsopoulos, K., Hardisson, D., et al. (2013). Functional Characterisation of Fusion Genes in Micropapillary Carcinomas of the Breast, LABORATORY INVESTIGATION, Vol.93, pp.57A-58A.

Natrajan, R., Wilkerson, P.M., Marchio, C., Lambros, M.B., Ng, C.K., Topfer, C., Kozarewa, I., Hakas, J., Mitsopoulos, K., Hardisson, D., et al. (2013). Functional Characterisation of Fusion Genes in Micropapillary Carcinomas of the Breast, MODERN PATHOLOGY, Vol.26, pp.57A-58A.

Ng, C.K., Gauthier, A., Wilkerson, P.M., Lambros, M.B., Arnoud, L., Lacroix-Triki, M., Penault-Llorca, F., Baranzelli, M.C., Sastre-Garau, X., Lord, C.J., et al. (2013). Characterisation of the Genetic Heterogeneity of Invasive Breast Cancers with Heterogeneous HER2 Overexpression and Gene Amplification, MODERN PATHOLOGY, Vol.26, p.58A.

Ng, C.K., Gauthier, A., Wilkerson, P.M., Lambros, M.B., Arnoud, L., Lacroix-Triki, M., Penault-Llorca, F., Baranzelli, M.C., Sastre-Garau, X., Lord, C.J., et al. (2013). Characterisation of the Genetic Heterogeneity of Invasive Breast Cancers with Heterogeneous HER2 Overexpression and Gene Amplification, LABORATORY INVESTIGATION, Vol.93, p.58A.

Carvalho, D., Mackay, A., Burford, A., Bjerke, L., Chen, L., Kozarewa, I., Lord, C., Ashworth, A., Hargrave, D., Reis, R., et al. (2013). INTEGRATED WHOLE GENOME AND RNA SEQUENCING IDENTIFIES NOVEL EXPRESSED FUSION TRANSCRIPTS IN PAEDIATRIC HIGH GRADE GLIOMA, NEURO-ONCOLOGY, Vol.15, p.25.

Dedes, K.J., Wilkerson, P., Wetterskog, D., Lambros, M.B., Natrajan, R., Tan, D.S., Campion-Flora, A., Rodrigues, D.N., Gauthier, A., Daley, F., et al. (2012). PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance, MODERN PATHOLOGY, Vol.25, p.265A.

Dedes, K.J., Wilkerson, P., Wetterskog, D., Lambros, M.B., Natrajan, R., Tan, D.S., Campion-Flora, A., Rodrigues, D.N., Gauthier, A., Daley, F., et al. (2012). PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance, LABORATORY INVESTIGATION, Vol.92, p.265A.

Leonard, A. & Wolff, J. (2012). ETOPOSIDE IMPROVES SURVIVAL IN HIGH GRADE GLIOMA: A META-ANALYSIS, NEURO-ONCOLOGY, Vol.14, p.56.

Nandhabalan, M., Bjerke, L., Bax, D., Carvalho, D., Bajrami, I., Ashworth, A., Lord, C., Hargrave, D., Reis, R., Workman, P., et al. (2012). H3F3A MUTATIONS IN PAEDIATRIC GLIOBLASTOMA REGULATE A SELF-RENEWAL GENE SIGNATURE, NEURO-ONCOLOGY, Vol.14, pp.65-66.

Carvalho, D., Bjerke, L., Bax, D., Chen, L., Kozarewa, I., Baker, S., Grundy, R., Ashworth, A., Lord, C., Hargrave, D., et al. (2012). IDENTIFICATION OF NOVEL FUSION GENES IN PAEDIATRIC HIGH GRADE GLIOMA, NEURO-ONCOLOGY, Vol.14, p.66.

Carvalho, D., Bjerke, L., Bax, D., Chen, L., Kozarewa, I., Baker, S., Grundy, R., Ashworth, A., Lord, C., Hargrave, D., et al. (2012). IDENTIFICATION OF NOVEL FUSION GENES IN PEDIATRIC HIGH-GRADE GLIOMA, NEURO-ONCOLOGY, Vol.14, p.116.

Pettitt, S.J., Rehman, F., Brough, R., Lord, C.J. & Ashworth, A. (2012). Haploid Genetic Screens to Identify Determinants of Drug Toxicity and Resistance, EUROPEAN JOURNAL OF CANCER, Vol.48, pp.42-43.

Carvalho, S., Aarts, M., Riffell, J., Torrance, C., Lord, C.J. & Ashworth, A. (2012). Identifying KRAS New Synthetic Lethality Relationships in Cancer, EUROPEAN JOURNAL OF CANCER, Vol.48, p.33.

Miller, R., Brough, R., Bajrami, I., Kaye, S., Banerjee, S., Lord, C. & Ashworth, A. (2012). Functional Profiling of Clear Cell Ovarian Cancer, EUROPEAN JOURNAL OF CANCER, Vol.48, p.33.

Miller, R., Brough, R., Bajrami, I., Kaye, S.B., Lord, C.J. & Ashworth, A. (2012). Functional profiling of clear cell ovarian cancer., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Rehman, F., Elliott, R., Brough, R., Frankum, J., Ragab, A., Lord, C.J. & Ashworth, A. (2012). Developing rational drug combination strategies for PARP inhibitors, JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Isacke, C.M., Murugaesu, N., Iravani, M., Johnson, D.A., Ashworth, A. & Lord, C.J. (2011). Tumour - Stroma Interactions in Breast Cancer Metastasis, EUROPEAN JOURNAL OF CANCER, Vol.47, p.S30.

Rajan, N., Burn, J., Langtry, J., Sieber-Blum, M., Lord, C.J. & Ashworth, A. (2011). Loss of organisation in CYLD defective tumours is associated with reduced DKK2 expression, Presented at Annual Meeting of the British-Society-for-Investigative-Dermatology, Univ Manchester, Manchester, ENGLAND. BRITISH JOURNAL OF DERMATOLOGY, Vol.164 (4), p.916.

Iorns, E.J., Ward, T.M., Dean, S., Jegg, A., Murugaesu, N., Sims, D., Lord, C., Ashworth, A., Hnatyszyn, J., Pegram, M., et al. (2011). Whole genome in vivo RNA interference screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor, CANCER RESEARCH, Vol.71.

Wardell, C.P., Walker, B.A., Johnson, D., Kozarewa, I., Fenwick, K., Lord, C., Ashworth, A., Davies, F.E. & Morgan, G.J. (2011). Exome Sequencing of the t(4;14) and t(11;14) Translocation Specific Subgroups of MM, BLOOD, Vol.118 (21), p.793.

Bax, D., Elliott, R., Bishop, R., Taylor, K., Marshall, L., Gaspar, N., Viana-Pereira, M., Reis, R., Renshaw, J., Ashworth, A., et al. (2011). HIGH THROUGHPUT DRUG SCREENING OF PAEDIATRIC GLIOMA CELL LINES, NEURO-ONCOLOGY, Vol.13, p.2.

Rajan, N., Lord, C.J., Clewes, O., Burn, J., Sieber-Blum, M. & Ashworth, A. (2010). Dysregulated tropomyosin receptor kinase signalling in CYLDtrunc/trunc tumours, Presented at Annual Meeting of the British-Society-for-Investigative-Dermatology, Edinburgh, SCOTLAND. BRITISH JOURNAL OF DERMATOLOGY, Vol.162 (4), pp.922-923.

Rajan, N., Lord, C.J., Clewes, O., Burn, J., Sieber-Blum, M. & Ashworth, A. (2010). Dysregulated tropomyosin receptor kinase signalling in CYLDtrunc/trunc tumours, Presented at 90th Annual Meeting of the British-Association-of-Deermatologists, Manchester, UNITED KINGDOM. BRITISH JOURNAL OF DERMATOLOGY, Vol.163, p.11.

Rajan, N., Gillinder, K., Lord, C., Langtry, J.A., Burn, J., Ashworth, A., Chaudhury, B. & Sieber-Blum, M. (2010). Unravelling cylindromas: insights into appendageal tumour patterning from patients with truncating CYLD mutations, Presented at 90th Annual Meeting of the British-Association-of-Deermatologists, Manchester, UNITED KINGDOM. BRITISH JOURNAL OF DERMATOLOGY, Vol.163, p.92.

Rajan, N., Elliott, R., Lord, C., Clewes, O., Burn, J., Sieber-Blum, M. & Ashworth, A. (2010). Dysregulated tropomyosin receptor kinase (Trk) signalling in CYLD mutant tumours, Presented at 40th Annual Meeting of the European-Society-for-Dermatological-Research (ESDR 2010), Helsinki, FINLAND. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol.130, p.S76.

Rajan, N., Elliott, R., Lord, C.J., Burn, J., Blum, M.S. & Ashworth, A. (2010). Advances in the development of new therapies for CYLD mutation carriers Targeting Trk, Presented at British Human Genetics Conference, Warwick, RI. JOURNAL OF MEDICAL GENETICS, Vol.47, p.S26.

Natrajan, R., Rodriguez-Pinilla, S.M., Lambros, M.B., Tan, D.S., Marchio, C., Vatcheva, R., Rayter, S., Moreno-Bueno, G., Fulford, L.G., Mackay, A., et al. (2009). Molecular Profiling of Grade III Invasive Ductal Breast Cancers Identifies PPM1D Amplification as a Therapeutic Target in Luminal and HER2 Tumours, Presented at 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA. MODERN PATHOLOGY, Vol.22, p.59A.

McCarthy, A., Lord, C.J., Savage, K., Grigoriadis, A., Smith, D.P., Weigelt, B., Reis-Filho, J.S. & Ashworth, A. (2009). Conditional Deletion of the LKB1 Gene in the Mouse Mammary Gland Induces Tumour Formation, Presented at 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA. LABORATORY INVESTIGATION, Vol.89, pp.56A-57A.

McCarthy, A., Lord, C.J., Savage, K., Grigoriadis, A., Smith, D.P., Weigelt, B., Reis-Filho, J.S. & Ashworth, A. (2009). Conditional Deletion of the LKB1 Gene in the Mouse Mammary Gland Induces Tumour Formation, Presented at 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA. MODERN PATHOLOGY, Vol.22, pp.56A-57A.

Natrajan, R., Rodriguez-Pinilla, S.M., Lambros, M.B., Tan, D.S., Marchio, C., Vatcheva, R., Rayter, S., Moreno-Bueno, G., Fulford, L.G., Mackay, A., et al. (2009). Molecular Profiling of Grade III Invasive Ductal Breast Cancers Identifies PPM1D Amplification as a Therapeutic Target in Luminal and HER2 Tumours, Presented at 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA. LABORATORY INVESTIGATION, Vol.89, p.59A.

Tutt, A., Lord, C.J. & Ashworth, A. (2008). PARP INHIBITORS, Presented at 33rd European-Society-for-Medical-Oncology Congress, Stockholm, SWEDEN. ANNALS OF ONCOLOGY, Vol.19, p.34.

Tutt, A.N., Lord, C.J., McCabe, N., Farmer, H., Turner, N., Martin, N.M., Jackson, S.P., Smith, G.C. & Ashworth, A. (2005). Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer, Presented at 70th Cold Spring Harbor Symposium on Quantitative Biology, Cold Spring Harbor, NY. Molecular Approaches to Controlling Cancer, Vol.70, pp.139-148.

Rhett, D.W. & Lord, C.J. (2001). Water weakening in sedimentary rocks, Presented at 38th US Rock Mechanics Symposium (DC Rocks 2001), WASHINGTON, D.C.. ROCK MECHANICS IN THE NATIONAL INTEREST, VOLS 1 AND 2, , pp.121-128.

Lord, C., Lyons, P., Brook, F., Gardner, R., Peterson, L., Wicker, L. & Todd, J. (1998). Evaluation of the candidacy of the Interleukin-2 gene as the Idd3 locus: Towards the functional assessment of fine mapped murine type 1 diabetes candidate variants, DIABETES, Vol.47, p.A198.

SUGHRUE, E.L., ADARME, R., JOHNSON, M.M., LORD, C.J. & PHILLIPS, M.D. (1991). DEMETALLIZATION OF ASPHALTENES - MODELING FEED AND PRODUCT MOLECULAR-SIZE DISTRIBUTIONS AND METAL DISTRIBUTION PARAMETERS, Presented at 5TH INTERNATIONAL SYMP ON CATALYST DEACTIVATION, EVANSTON, IL. CATALYST DEACTIVATION 1991, Vol.68, pp.281-288.

COLVIN, D.P., LORD, C.J., BISHOP, G.G., ENGEL, T.W. & PATRA, A.L. (1991). A FALL INTERVENTION MOBILITY AID SYSTEM FOR ELDERLY AND REHABILITATIVE POPULATIONS, Presented at 1991 ANNUAL INTERNATIONAL CONF OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOC, ORLANDO, FL. PROCEEDINGS OF THE ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOL 13, PTS 1-5, , pp.1936-1937.

LORD, C.J. & COLVIN, D.P. (1991). FALLS IN THE ELDERLY - DETECTION AND ASSESSMENT, Presented at 1991 ANNUAL INTERNATIONAL CONF OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOC, ORLANDO, FL. PROCEEDINGS OF THE ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOL 13, PTS 1-5, , pp.1938-1939.

LORD, C.J., COLVIN, D.P., THURMAN, R.D. & DUNCAN, J.L. (1988). COMPUTER-SIMULATION OF NOVEL AUGMENTATIVE COMMUNICATIONS DEVICES, Presented at 1989 ANNUAL INTERNATIONAL CONF OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOC, NEW ORLEANS, LA. PROCEEDINGS OF THE ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, PTS 1-4, , pp.1586-1587.

In this section

Research overview Research projects Publications
We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.